For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Clinical stage drug developer Syntara Limited (formerly Pharmaxis Ltd; ASX: PXS)1 has received a R&D tax incentive of $5,205,123 in relation to the 2023 financial year. The Company’s cash balances will increase by approximately $700k after repayment of the $4.4 million loan and associated charges advanced by Paddington Street Finance in August 2023.
Pharmaxis CEO Gary Phillips said, “The R&D tax incentive is a significant source of non-dilutive funding for the Company’s clinical development pipeline including PXS-5505 in myelofibrosis where the next arm of a phase 2 trial in combination with standard of care is expected to shortly dose its first patients.”
Syntara Limited was renamed from Pharmaxis Ltd on 4 December 2023. The new company name and code (SNT) will be effective on the ASX on 8 December 2023.
Clinical stage drug developer Syntara Limited today announced that the Australian Securities and Investment Commission has issued a Certificate of Registration on Change of Name from Pharmaxis Ltd to Syntara Limited. This follows approval at last week’s 2023 annual general meeting where the resolution to change the name was supported by 98% of voting shareholders.
The change in the Company’s ASX code from PXS to SNT is currently being processed by the ASX, with trading under the new code expected to commence by Friday 8 December 2023.Read full ASX announcement – pdf
Syntara doses first patient in Phase 2 trial of patients with sleep disorder at risk of Parkinson’s disease
Clinical stage drug developer Syntara1 today announced that the first patient has been dosed in its randomised double-blind placebo controlled Phase 2 study of the Syntara drug discovery PXS-4728 studying patients with isolated Rapid Eye Movement Sleep Behaviour Disorder (iRBD) who are at risk of Parkinson’s disease.
The first patient has been dosed in Sydney in a multi-national trial that is majority funded by the Parkinson’s Virtual Biotech, the international drug discovery and development program founded by Parkinson’s UK.